Public Sector Pension Investment Board Purchases 903,448 Shares of Boston Scientific Corporation $BSX

Public Sector Pension Investment Board raised its position in Boston Scientific Corporation (NYSE:BSX) by 98.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,823,481 shares of the medical equipment provider’s stock after buying an additional 903,448 shares during the quarter. Boston Scientific accounts for 0.7% of Public Sector Pension Investment Board’s holdings, making the stock its 28th biggest holding. Public Sector Pension Investment Board owned 0.12% of Boston Scientific worth $178,026,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of BSX. Brighton Jones LLC increased its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the period. CWM LLC grew its position in shares of Boston Scientific by 36.9% during the 2nd quarter. CWM LLC now owns 51,316 shares of the medical equipment provider’s stock worth $5,512,000 after purchasing an additional 13,840 shares in the last quarter. Boston Trust Walden Corp increased its holdings in shares of Boston Scientific by 405.8% during the second quarter. Boston Trust Walden Corp now owns 33,667 shares of the medical equipment provider’s stock worth $3,616,000 after purchasing an additional 27,011 shares during the period. Bayforest Capital Ltd increased its holdings in shares of Boston Scientific by 511.6% during the second quarter. Bayforest Capital Ltd now owns 2,263 shares of the medical equipment provider’s stock worth $243,000 after purchasing an additional 1,893 shares during the period. Finally, Harbour Investments Inc. raised its position in shares of Boston Scientific by 17.3% in the second quarter. Harbour Investments Inc. now owns 6,308 shares of the medical equipment provider’s stock valued at $678,000 after buying an additional 929 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The SEC filing for this sale provides additional information. 0.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on BSX. Stifel Nicolaus reduced their price target on Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. UBS Group cut their target price on Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Barclays decreased their price target on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 3rd. Oppenheimer dropped their price target on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. Finally, Mizuho reduced their price objective on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $109.43.

Boston Scientific Price Performance

Shares of BSX stock opened at $74.09 on Friday. Boston Scientific Corporation has a twelve month low of $72.69 and a twelve month high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The business has a fifty day simple moving average of $91.39 and a 200 day simple moving average of $97.90. The company has a market cap of $109.83 billion, a P/E ratio of 38.19, a P/E/G ratio of 1.02 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the previous year, the firm earned $0.70 earnings per share. The business’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.